The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 - - IVT ...

Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...

FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...

Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...

SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD) appeared to have no major safety issues or significantly affect either ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) focused on one condition or the other, retina specialists commonly encounter ...

CTx001 has previously received FDA IND clearance and will be evaluated in Opti-GAIN, a first-in-human Phase I/II clinical trial MUNICH, Jan. 8, 2026 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), ...